NewAmsterdam Pharma Company N.V.
DE ˙ DB
27,34 € ↑0,15 (0,55%)
2026-06-05
PREZZO DELLE AZIONI
SecurityDE:KH6 / NewAmsterdam Pharma Company N.V.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership886,616 shares
Latest Disclosed Value $ 28,380,578
BlackRock, Inc. reports 4.33% increase in ownership of KH6 / NewAmsterdam Pharma Company N.V.

On May 13, 2026 - BlackRock, Inc. filed a 13F-HR form disclosing ownership of 886,616 shares of NewAmsterdam Pharma Company N.V. (DE:KH6) valued at $22,165,400 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 849,779 shares of NewAmsterdam Pharma Company N.V.. This represents a change in shares of 4.33% during the quarter. The current value of the position is $24,240,081 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 886,616 36,837 4.33 28,381 -4.80 0.0000
2026-02-12 2025-12-31 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 849,779 227,264 36.51 29,810 68.38 0.0005
2025-11-12 2025-09-30 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 622,515 50,842 8.89 17,704 71.02 0.0003
2025-08-12 2025-06-30 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 571,673 73,692 14.80 10,353 1.56 0.0002
2025-05-02 2025-03-31 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 497,981 56,463 12.79 10,194 -10.17 0.0002
2025-02-07 2024-12-31 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 441,518 374,845 562.21 11,347 925.95 0.0002
2024-11-13 2024-09-30 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 66,673 25,028 60.10 1,107 38.25 0.0000
2024-08-13 2024-06-30 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 41,645 30,425 271.17 800 201.89 0.0000
2024-05-10 2024-03-31 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 11,220 -11,721 -51.09 265 3.52 0.0000
2024-02-13 2023-12-31 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 22,941 0 0.00 256 20.75 0.0000
2023-11-13 2023-09-30 13F NEWAMSTERDAM PHARMA ORDINARY SHARES N62509109 22,941 22,941 212 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.